Table 7.
Samples | NC vs UC | SYD vs UC | NC vs UC vs SYD | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
PLS-DA | OPLS-DA | PLS-DA | OPLS-DA | PCA | |||||||
ESI (+) | ESI (-) | ESI (+) | ESI (-) | ESI (+) | ESI (-) | ESI (+) | ESI (-) | ESI (+) | ESI (-) | ||
Feces | Significant components | 3 | 3 | 3 | 4 | 2 | 2 | 2 | 2 | 6 | 6 |
R2X | 0.605 | 0.615 | 0.605 | 0.650 | 0.480 | 0.424 | 0.480 | 0.424 | 0.735 | 0.717 | |
Q2 | 0.935 | 0.900 | 0.926 | 0.898 | 0.811 | 0.709 | 0.822 | 0.723 | 0.546 | 0.496 | |
p | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | – | – | |
Livers | Significant components | 3 | 4 | 2 | 8 | 3 | 2 | 5 | 3 | 5 | 6 |
R2X | 0.652 | 0.690 | 0.596 | 0.843 | 0.525 | 0.348 | 0.690 | 0.512 | 0.758 | 0.770 | |
Q2 | 0.972 | 0.862 | 0.961 | 0.930 | 0.747 | 0.354 | 0.846 | 0.477 | 0.466 | 0.533 | |
p | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | – | – | |
Serum | Significant components | 3 | 4 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 2 |
R2X | 0.729 | 0.915 | 0.729 | 0.824 | 0.480 | 0.562 | 0.626 | 0.562 | 0.733 | 0.753 | |
Q2 | 0.912 | 0.909 | 0.904 | 0.677 | 0.132 | 0.395 | 0.264 | 0.412 | 0.413 | 0.273 | |
p | <0.05 | <0.05 | <0.05 | <0.05 | >0.05 | <0.05 | >0.05 | <0.05 | – | – | |
Urine | Significant components | 2 | 2 | 5 | 2 | 3 | 2 | 2 | 3 | 3 | 5 |
R2X | 0.493 | 0.521 | 0.747 | 0.521 | 0.655 | 0.535 | 0.585 | 0.618 | 0.622 | 0.759 | |
Q2 | 0.908 | 0.900 | 0.943 | 0.907 | 0.933 | 0.882 | 0.900 | 0.891 | 0.402 | 0.445 | |
p | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 | – | – |
Notes: R2X represents the goodness of fit of models; Q2 represents the predictability of models; p values were calculated by CV-ANOVA; PLS-DA and OPLS-DA model is valid when p < 0.05. NC vs UC: compare Normal Control group with Model group; SYD vs UC: compare SYD group with Model group; NC vs UC vs SYD: compare Normal Control, SYD group with Model group.